Analyst reports.


This information is provided for information purposes only. The opinions, estimates, forecasts or any analysis do not represent the opinions, forecasts, or any analysis of our Company or management or staff. We do not by its reference imply any concurrence with the independently provided opinions, estimates or forecasts.

Analyst Reports 2024

Analyst Reports 2024
April 19th 2024

Ladenburg Thalmann - Autoimmune Program is Advancing into Clinic; Reaffirm Buy, $8.30 PT (Analyst: Ahu Demir, PhD)

For a copy of this research report please contact your Ladenburg Thalmann advisor

April 18th 2024

Wilsons - Adding Autoimmune to the indication list; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)

April 4th 2024

Bell Potter - Thoughts Ahead of TACTI-003 Readout; Maintain Buy, A$0.65 tgt (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

March 27th 2024

CLSA - Checking in; Maintain Buy, A$0.95 tgt (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

March 6th 2024

Ladenburg Thalmann - Next Is Dose Optimization for BC Program; Reiterate Buy, $8.30 PT (Analyst: Ahu Demir, PhD)

For a copy of this research report please contact your Ladenburg Thalmann advisor

March 6th 2024

Baird - First Data on Highest Dose Ever of Efti Includes a Complete Response; Rated Outperform, $7 tgt (Analyst: Joel L. Beatty, MD, CFA)

For a copy of this research report please contact your Baird advisor

March 5th 2024

Wilsons - Dose it higher? Now an option; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)

March 5th 2024

CLSA - Nearing the Checkpoint; Upcoming HNSCC trial readout & Ph3 NSCLC progress key focus in CY24; Mtn Buy, A$0.95 Tgt (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

March 4th 2024

Bell Potter - Multiple Indications Advancing; Maintain Buy, Raise tgt to A$0.65 (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

February 29th 2024

Ladenburg Thalmann - Eyes Are on Controlled Study (TACTI-003) Results; Reaffirm Buy, $8.30 PT (Analyst: Ahu Demir, PhD)

For a copy of this research report please contact your Ladenburg Thalmann advisor

February 26th 2024

goetzpartners securities - Efti MoA strong durable in multiple cancers; Reit Buy, A$2.74 tgt (Analyst: Dr Chris Redhead)

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.